#BEGIN_DRUGCARD DB02255

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C20H28N4O4

# Chemical_IUPAC_Name:
(2R)-N-hydroxy-N'-[(1S)-2-(1H-indol-3-yl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
GM6001

# HET_ID:
GM6

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C20H28N4O4/c1-12(2)8-13(10-18(25)24-28)19(26)23-17(20(27)21-3)9-14-11-22-16-7-5-4-6-15(14)16/h4-7,11-13,17,22,28H,8-10H2,1-3H3,(H,21,27)(H,23,26)(H,24,25)/t13-,17+/m1/s1

# InChI_Key:
InChIKey=NITYDPDXAAFEIT-DYVFJYSZSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2255

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
388.4607

# Molecular_Weight_Mono:
388.211055404

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1PWU

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.23

# Predicted_LogS:
-4

# Predicted_Water_Solubility:
4.08e-02 g/l

# Primary_Accession_No:
DB02255

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
132519

# PubChem_Substance_ID:
46506673

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01618

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@](CC(C)C)(CC(=O)NO)C(=O)N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(=O)NC

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:57 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M29081

# Drug_Target_1_GenBank_ID_Protein:
143144

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
lef

# Drug_Target_1_Gene_Sequence:
>2430 bp
ATGAATATAAAAAAAGAATTTATAAAAGTAATTAGTATGTCATGTTTAGTAACAGCAATT
ACTTTGAGTGGTCCCGTCTTTATCCCCCTTGTACAGGGGGCGGGCGGTCATGGTGATGTA
GGTATGCACGTAAAAGAGAAAGAGAAAAATAAAGATGAGAATAAGAGAAAAGATGAAGAA
CGAAATAAAACACAGGAAGAGCATTTAAAGGAAATCATGAAACACATTGTAAAAATAGAA
GTAAAAGGGGAGGAAGCTGTTAAAAAAGAGGCAGCAGAAAAGCTACTTGAGAAAGTACCA
TCTGATGTTTTAGAGATGTATAAAGCAATTGGAGGAAAGATATATATTGTGGATGGTGAT
ATTACAAAACATATATCTTTAGAAGCATTATCTGAAGATAAGAAAAAAATAAAAGACATT
TATGGGAAAGATGCTTTATTACATGAACATTATGTATATGCAAAAGAAGGATATGAACCC
GTACTTGTAATCCAATCTTCGGAAGATTATGTAGAAAATACTGAAAAGGCACTGAACGTT
TATTATGAAATAGGTAAGATATTATCAAGGGATATTTTAAGTAAAATTAATCAACCATAT
CAGAAATTTTTAGATGTATTAAATACCATTAAAAATGCATCTGATTCAGATGGACAAGAT
CTTTTATTTACTAATCAGCTTAAGGAACATCCCACAGACTTTTCTGTAGAATTCTTGGAA
CAAAATAGCAATGAGGTACAAGAAGTATTTGCGAAAGCTTTTGCATATTATATCGAGCCA
CAGCATCGTGATGTTTTACAGCTTTATGCACCGGAAGCTTTTAATTACATGGATAAATTT
AACGAACAAGAAATAAATCTATCCTTGGAAGAACTTAAAGATCAACGGATGCTGTCAAGA
TATGAAAAATGGGAAAAGATAAAACAGCACTATCAACACTGGAGCGATTCTTTATCTGAA
GAAGGAAGAGGACTTTTAAAAAAGCTGCAGATTCCTATTGAGCCAAAGAAAGATGACATA
ATTCATTCTTTATCTCAAGAAGAAAAAGAGCTTCTAAAAAGAATACAAATTGATAGTAGT
GATTTTTTATCTACTGAGGAAAAAGAGTTTTTAAAAAAGCTACAAATTGATATTCGTGAT
TCTTTATCTGAAGAAGAAAAAGAGCTTTTAAATAGAATACAGGTGGATAGTAGTAATCCT
TTATCTGAAAAAGAAAAAGAGTTTTTAAAAAAGCTGAAACTTGATATTCAACCATATGAT
ATTAATCAAAGGTTGCAAGATACAGGAGGGTTAATTGATAGTCCGTCAATTAATCTTGAT
GTAAGAAAGCAGTATAAAAGGGATATTCAAAATATTGATGCTTTATTACATCAATCCATT
GGAAGTACCTTGTACAATAAAATTTATTTGTATGAAAATATGAATATCAATAACCTTACA
GCAACCCTAGGTGCGGATTTAGTTGATTCCACTGATAATACTAAAATTAATAGAGGTATT
TTCAATGAATTCAAAAAAAATTTCAAATATAGTATTTCTAGTAACTATATGATTGTTGAT
ATAAATGAAAGGCCTGCATTAGATAATGAGCGTTTGAAATGGAGAATCCAATTATCACCA
GATACTCGAGCAGGATATTTAGAAAATGGAAAGCTTATATTACAAAGAAACATCGGTCTG
GAAATAAAGGATGTACAAATAATTAAGCAATCCGAAAAAGAATATATAAGGATTGATGCG
AAAGTAGTGCCAAAGAGTAAAATAGATACAAAAATTCAAGAAGCACAGTTAAATATAAAT
CAGGAATGGAATAAAGCATTAGGGTTACCAAAATATACAAAGCTTATTACATTCAACGTG
CATAATAGATATGCATCCAATATTGTAGAAAGTGCTTATTTAATATTGAATGAATGGAAA
AATAATATTCAAAGTGATCTTATAAAAAAGGTAACAAATTACTTAGTTGATGGTAATGGA
AGATTTGTTTTTACCGATATTACTCTCCCTAATATAGCTGAACAATATACACATCAAGAT
GAGATATATGAGCAAGTTCATTCAAAAGGGTTATATGTTCCAGAATCCCGTTCTATATTA
CTCCATGGACCTTCAAAAGGTGTAGAATTAAGGAATGATAGTGAGGGTTTTATACACGAA
TTTGGACATGCTGTGGATGATTATGCTGGATATCTATTAGATAAGAACCAATCTGATTTA
GTTACAAATTCTAAAAAATTCATTGATATTTTTAAGGAAGAAGGGAGTAATTTAACTTCG
TATGGGAGAACAAATGAAGCGGAATTTTTTGCAGAAGCCTTTAGGTTAATGCATTCTACG
GACCATGCTGAACGTTTAAAAGTTCAAAAAAATGCTCCGAAAACTTTCCAATTTATTAAC
GATCAGATTAAGTTCATTATTAACTCATAA

# Drug_Target_1_General_Function:
Involved in protease activity

# Drug_Target_1_General_References:
10338520	Tang G, Leppla SH: Proteasome activity is required for anthrax lethal toxin to kill macrophages. Infect Immun. 1999 Jun;67(6):3055-60.
10475971	Duesbery NS, Vande Woude GF: Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase. J Appl Microbiol. 1999 Aug;87(2):289-93.
10515943	Okinaka RT, Cloud K, Hampton O, Hoffmaster AR, Hill KK, Keim P, Koehler TM, Lamke G, Kumano S, Mahillon J, Manter D, Martinez Y, Ricke D, Svensson R, Jackson PJ: Sequence and organization of pXO1, the large Bacillus anthracis plasmid harboring the anthrax toxin genes. J Bacteriol. 1999 Oct;181(20):6509-15.
11104681	Vitale G, Bernardi L, Napolitani G, Mock M, Montecucco C: Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem J. 2000 Dec 15;352 Pt 3:739-45.
11162493	Gupta P, Singh A, Chauhan V, Bhatnagar R: Involvement of residues 147VYYEIGK153 in binding of lethal factor to protective antigen of Bacillus anthracis. Biochem Biophys Res Commun. 2001 Jan 12;280(1):158-63.
11595637	Brossier F, Mock M: Toxins of Bacillus anthracis. Toxicon. 2001 Nov;39(11):1747-55.
11700563	Pannifer AD, Wong TY, Schwarzenbacher R, Renatus M, Petosa C, Bienkowska J, Lacy DB, Collier RJ, Park S, Leppla SH, Hanna P, Liddington RC: Crystal structure of the anthrax lethal factor. Nature. 2001 Nov 8;414(6860):229-33.
12004073	Read TD, Salzberg SL, Pop M, Shumway M, Umayam L, Jiang L, Holtzapple E, Busch JD, Smith KL, Schupp JM, Solomon D, Keim P, Fraser CM: Comparative genome sequencing for discovery of novel polymorphisms in Bacillus anthracis. Science. 2002 Jun 14;296(5575):2028-33. Epub 2002 May 9.
12067380	Adone R, Pasquali P, La Rosa G, Marianelli C, Muscillo M, Fasanella A, Francia M, Ciuchini F: Sequence analysis of the genes encoding for the major virulence factors of Bacillus anthracis vaccine strain 'Carbosap'. J Appl Microbiol. 2002;93(1):117-21.
12113932	Singh A, Chauhan V, Sodhi A, Bhatnagar R: Asp 187 and Phe 190 residues in lethal factor are required for the expression of anthrax lethal toxin activity. FEMS Microbiol Lett. 2002 Jul 2;212(2):183-6.
2509294	Bragg TS, Robertson DL: Nucleotide sequence and analysis of the lethal factor gene (lef) from Bacillus anthracis. Gene. 1989 Sep 1;81(1):45-54.
7851740	Kochi SK, Schiavo G, Mock M, Montecucco C: Zinc content of the Bacillus anthracis lethal factor. FEMS Microbiol Lett. 1994 Dec 15;124(3):343-8.
8051039	Sirard JC, Mock M, Fouet A: The three Bacillus anthracis toxin genes are coordinately regulated by bicarbonate and temperature. J Bacteriol. 1994 Aug;176(16):5188-92.
8942659	Wang XM, Mock M, Ruysschaert JM, Cabiaux V: Secondary structure of anthrax lethal toxin proteins and their interaction with large unilamellar vesicles: a fourier-transform infrared spectroscopy approach. Biochemistry. 1996 Nov 26;35(47):14939-46.
9573135	Hammond SE, Hanna PC: Lethal factor active-site mutations affect catalytic activity in vitro. Infect Immun. 1998 May;66(5):2374-8.
9703991	Vitale G, Pellizzari R, Recchi C, Napolitani G, Mock M, Montecucco C: Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Biophys Res Commun. 1998 Jul 30;248(3):706-11.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2489

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
93771

# Drug_Target_1_Name:
Lethal factor

# Drug_Target_1_Number_of_Residues:
809

# Drug_Target_1_PDB_ID:
1PWV

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF07737	ATLF
PF09156	Anthrax-tox_M

# Drug_Target_1_Protein_Sequence:
>Lethal factor precursor
MNIKKEFIKVISMSCLVTAITLSGPVFIPLVQGAGGHGDVGMHVKEKEKNKDENKRKDEE
RNKTQEEHLKEIMKHIVKIEVKGEEAVKKEAAEKLLEKVPSDVLEMYKAIGGKIYIVDGD
ITKHISLEALSEDKKKIKDIYGKDALLHEHYVYAKEGYEPVLVIQSSEDYVENTEKALNV
YYEIGKILSRDILSKINQPYQKFLDVLNTIKNASDSDGQDLLFTNQLKEHPTDFSVEFLE
QNSNEVQEVFAKAFAYYIEPQHRDVLQLYAPEAFNYMDKFNEQEINLSLEELKDQRMLAR
YEKWEKIKQHYQHWSDSLSEEGRGLLKKLQIPIEPKKDDIIHSLSQEEKELLKRIQIDSS
DFLSTEEKEFLKKLQIDIRDSLSEEEKELLNRIQVDSSNPLSEKEKEFLKKLKLDIQPYD
INQRLQDTGGLIDSPSINLDVRKQYKRDIQNIDALLHQSIGSTLYNKIYLYENMNINNLT
ATLGADLVDSTDNTKINRGIFNEFKKNFKYSISSNYMIVDINERPALDNERLKWRIQLSP
DTRAGYLENGKLILQRNIGLEIKDVQIIKQSEKEYIRIDAKVVPKSKIDTKIQEAQLNIN
QEWNKALGLPKYTKLITFNVHNRYASNIVESAYLILNEWKNNIQSDLIKKVTNYLVDGNG
RFVFTDITLPNIAEQYTHQDEIYEQVHSKGLYVPESRSILLHGPSKGVELRNDSEGFIHE
FGHAVDDYAGYLLDKNQSDLVTNSKKFIDIFKEEGSNLTSYGRTNEAEFFAEAFRLMHST
DHAERLKVQKNAPKTFQFINDQIKFIINS

# Drug_Target_1_Reaction:
lethal toxin

# Drug_Target_1_Signals:
1-33

# Drug_Target_1_Specific_Function:
One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. LF is the lethal factor that, when associated with PA, causes death. LF is not toxic by itself. It is a protease that cleaves the N-terminal of most dual specificity mitogen-activated protein kinase kinases (MAPKKs or MAP2Ks) (except for MAP2K5). Cleavage invariably occurs within the N-terminal proline-rich region preceding the kinase domain, thus disrupting a sequence involved in directing specific protein-protein interactions necessary for the assembly of signaling complexes. There may be other cytosolic targets of LF involved in cytotoxicity. The proteasome may mediate a toxic process initiated by LF in the cell cytosol involving degradation of unidentified molecules that are essential for macrophage homeostasis. This is an early step in LeTx intoxication, but it is downstream of the cleavage by LF of MEK1 or other putative substrates

# Drug_Target_1_SwissProt_ID:
P15917

# Drug_Target_1_SwissProt_Name:
LEF_BACAN

# Drug_Target_1_Synonyms:
Anthrax lethal toxin endopeptidase component
EC 3.4.24.83
LF
Lethal factor precursor

# Drug_Target_1_Theoretical_pI:
5.69

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Isoform 2:Secreted

# Drug_Target_2_Chromosome_Location:
8

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
AF137334

# Drug_Target_2_GenBank_ID_Protein:
4583505

# Drug_Target_2_GeneCard_ID:
ADAM28

# Drug_Target_2_Gene_Name:
ADAM28

# Drug_Target_2_Gene_Sequence:
>2328 bp
ATGTTGCAAGGTCTCCTGCCAGTCAGTCTCCTCCTCTCTGTTGCAGTAAGTGCTATAAAA
GAACTCCCTGGGGTGAAGAAGTATGAAGTGGTTTATCCTATAAGACTTCATCCACTGCAT
AAAAGAGAGGCCAAAGAGCCAGAGCAACAGGAACAATTTGAAACTGAATTAAAGTATAAA
ATGACAATTAATGGAAAAATTGCAGTGCTTTATTTGAAAAAAAACAAGAACCTCCTTGCA
CCAGGCTACACGGAAACATATTATAATTCCACTGGAAAGGAGATCACCACAAGCCCACAA
ATTATGGATGATTGTTATTATCAAGGACATATTCTTAATGAAAAGGTTTCTGACGCTAGC
ATCAGCACATGTAGGGGTCTAAGGGGCTACTTCAGTCAGGGGGATCAAAGATACTTTATT
GAACCTTTAAGCCCCATACATCGGGATGGACAGGAGCATGCACTCTTCAAGTATAACCCT
GATGAAAAGAATTATGACAGCACCTGTGGGATGGATGGTGTGTTGTGGGCCCACGATTTG
CAGCAGAACATTGCCCTACCTGCCACCAAACTAGTAAAATTGAAAGACAGGAAGGTTCAG
GAACATGAGAAATACATAGAATATTATCTGGTCCTGGATAATGGTGAGTTTAAAAGGTAC
AATGAGAATCAAGATGAGATCAGAAAGAGGGTATTTGAGATGGCTAATTATGTCAACATG
CTTTATAAAAAGCTCAATACTCATGTGGCCTTAGTTGGTATGGAAATCTGGACTGACAAG
GATAAGATAAAGATAACCCCAAATGCAAGCTTCACCTTGGAGAATTTTTCTAAATGGAGG
GGGAGTGTTCTCTCAAGAAGAAAGCGTCATGATATTGCTCAGTTAATCACAGCAACAGAA
CTTGCTGGAACGACTGTGGGTCTTGCATTTATGTCTACAATGTGTTCTCCTTATTCTGTT
GGCGTTGTTCAGGACCACAGCGATAATCTTCTTAGAGTTGCAGGGACAATGGCACATGAA
ATGGGCCACAACTTTGGAATGTTTCATGACGACTATTCTTGCAAGTGTCCTTCTACAATA
TGTGTGATGGACAAAGCACTGAGCTTCTATATACCCACAGACTTCAGTTCCTGCAGCCGT
CTCAGCTATGACAAGTTTTTTGAAGATAAATTATCAAATTGCCTCTTTAATGCTCCATTG
CCTACAGATATCATATCCACTCCAATTTGTGGGAACCAGTTGGTGGAAATGGGAGAGGAC
TGTGATTGTGGGACATCTGAGGAATGTACCAATATTTGCTGTGATGCTAAGACATGTAAA
ATCAAAGCAACTTTTCAATGTGCATTAGGAGAATGTTGTGAAAAATGCCAATTTAAAAAG
GCTGGGATGGTGTGCAGACCAGCAAAAGATGAGTGCGACCTGCCTGAAATGTGTAATGGT
AAATCTGGTAATTGTCCTGATGATAGATTCCAAGTCAATGGCTTCCCTTGCCATCACGGG
AAGGGCCACTGCTTGATGGGCACATGCCCCACACTGCGGGAGCAGTGCACAGAGCTGTGG
GGACCAGGAACTGAGGTTGCAGATAAGTCATGTTACAACAGGAATGAAGGTGGGTCAAAG
TACGGGTACTGTCGCAGAGTGGATGACACACTCATTCCCTGCAAAGCAAATGATACCATG
TGTGGGAAGTTGTTCTGTCAAGGTGGGTCGGATAATTTGCCCTGGAAAGGACGGATAGTG
ACTTTCCTGACATGTAAAACATTTGATCCTGAAGACACAAGTCAAGAAATAGGCATGGTG
GCCAATGGAACTAAGTGTGGCGATAACAAGGTTTGCATTAATGCAGAATGTGTGGATATT
GAGAAAGCCTACAAATCAACCAATTGCTCATCCAAGTGCAAAGGACATGCTGTGTGTGAC
CATGAGCTCCAGTGTCAATGTGAGGAAGGATGGATCCCTCCCGACTGCGATGACTCCTCA
GTGGTCTTCCACTTCTCCATTGTGGTTGGGGTGCTGTTCCCAATGGCGGTCATTTTTGTG
GTGGTTGCTATGGTAATCCGGCACCAGAGCTCCAGAGAAAAGCAGAAGAAAGATCAGAGG
CCACTATCTACCACTGGCACCAGGCCACACAAACAGAAGAGGAAACCCCAGATGGTAAAG
GCTGTTCAACCCCAAGAGATGAGTCAGATGAAGCCCCATGTGTATGATCTGCCAGTAGAA
GGCAATGAGCCCCCAGCCTCTTTTCATAAAGACACAAACGCACTTCCCCCTACTGTTTTC
AAGGATAATCCAATGTCTACACCTAAGGACTCAAATCCAGAAGCATGA

# Drug_Target_2_General_Function:
Involved in metalloendopeptidase activity

# Drug_Target_2_General_References:
10506182	Roberts CM, Tani PH, Bridges LC, Laszik Z, Bowditch RD: MDC-L, a novel metalloprotease disintegrin cysteine-rich protein family member expressed by human lymphocytes. J Biol Chem. 1999 Oct 8;274(41):29251-9.
10587367	Jury JA, Perry AC, Hall L: Identification, sequence analysis and expression of transcripts encoding a putative metalloproteinase, eMDC II, in human and macaque epididymis. Mol Hum Reprod. 1999 Dec;5(12):1127-34.

# Drug_Target_2_HGNC_ID:
GNC:206

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6374

# Drug_Target_2_Locus:
8p21.2

# Drug_Target_2_Molecular_Weight:
87180.0

# Drug_Target_2_Name:
Disintegrin and metalloproteinase domain-containing protein 28

# Drug_Target_2_Number_of_Residues:
775

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00200	Disintegrin
PF01421	Reprolysin
PF01562	Pep_M12B_propep
PF08516	ADAM_CR

# Drug_Target_2_Protein_Sequence:
>Disintegrin and metalloproteinase domain-containing protein 28
MLQGLLPVSLLLSVAVSAIKELPGVKKYEVVYPIRLHPLHKREAKEPEQQEQFETELKYK
MTINGKIAVLYLKKNKNLLAPGYTETYYNSTGKEITTSPQIMDDCYYQGHILNEKVSDAS
ISTCRGLRGYFSQGDQRYFIEPLSPIHRDGQEHALFKYNPDEKNYDSTCGMDGVLWAHDL
QQNIALPATKLVKLKDRKVQEHEKYIEYYLVLDNGEFKRYNENQDEIRKRVFEMANYVNM
LYKKLNTHVALVGMEIWTDKDKIKITPNASFTLENFSKWRGSVLSRRKRHDIAQLITATE
LAGTTVGLAFMSTMCSPYSVGVVQDHSDNLLRVAGTMAHEMGHNFGMFHDDYSCKCPSTI
CVMDKALSFYIPTDFSSCSRLSYDKFFEDKLSNCLFNAPLPTDIISTPICGNQLVEMGED
CDCGTSEECTNICCDAKTCKIKATFQCALGECCEKCQFKKAGMVCRPAKDECDLPEMCNG
KSGNCPDDRFQVNGFPCHHGKGHCLMGTCPTLQEQCTELWGPGTEVADKSCYNRNEGGSK
YGYCRRVDDTLIPCKANDTMCGKLFCQGGSDNLPWKGRIVTFLTCKTFDPEDTSQEIGMV
ANGTKCGDNKVCINAECVDIEKAYKSTNCSSKCKGHAVCDHELQCQCEEGWIPPDCDDSS
VVFHFSIVVGVLFPMAVIFVVVAMVIRHQSSREKQKKDQRPLSTTGTRPHKQKRKPQMVK
AVQPQEMSQMKPHVYDLPVEGNEPPASFHKDTNALPPTVFKDNPMSTPKDSNPEA

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-18

# Drug_Target_2_Specific_Function:
May play a role in the adhesive and proteolytic events that occur during lymphocyte emigration or may function in ectodomain shedding of lymphocyte surface target proteins, such as FASL and CD40L. May be involved in sperm maturation

# Drug_Target_2_SwissProt_ID:
Q9UKQ2

# Drug_Target_2_SwissProt_Name:
ADA28_HUMAN

# Drug_Target_2_Synonyms:
ADAM 28
Epididymial metalloproteinase-like, disintegrin-like, and cysteine-rich protein II
MDC-L
Metalloproteinase-like, disintegrin-like, and cysteine-rich protein L
eMDC II

# Drug_Target_2_Theoretical_pI:
6.80

# Drug_Target_2_Transmembrane_Regions:
666-686

# Drug_Target_3_Cellular_Location:
Secreted, extracellular space, extracellular matrix (By similarity)

# Drug_Target_3_Chromosome_Location:
1

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
M55172

# Drug_Target_3_GenBank_ID_Protein:
178259

# Drug_Target_3_GeneCard_ID:
ACAN

# Drug_Target_3_Gene_Name:
ACAN

# Drug_Target_3_Gene_Sequence:
>6951 bp
ATGACCACTTTACTCTGGGTTTTCGTGACTCTGAGGGTCATCACTGCAGCTGTCACTGTA
GAAACTTCAGACCATGACAACTCGCTGAGTGTCAGCATCCCCCAACCGTCCCCGCTGAGG
GTCCTCCTGGGGACCTCCCTCACCATCCCCTGCTATTTCATCGACCCCATGCACCCTGTG
ACCACCGCCCCTTCTACCGCCCCACTGGCCCCAAGAATCAAGTGGAGCCGTGTGTCCAAG
GAGAAGGAGGTAGTGCTGCTGGTGGCCACTGAAGGGCGCGTGCGGGTCAACAGTGCCTAT
CAGGACAAGGTCTCACTGCCCAACTACCCGGCCATCCCCAGTGACGCCACCTTGGAAGTC
CAGAGCCTGCGCTCCAATGACTCTGGGGTCTACCGCTGCGAGGTGATGCATGGCATCGAG
GACAGCGAGGCCACCCTGGAAGTCGTGGTGAAAGGCATCGTGTTCCATTACAGAGCCATC
TCTACACGCTACACCCTCGACTTTGACAGGGCGCAGCGGGCCTGCCTGCAGAACAGTGCC
ATCATTGCCACGCCTGAGCAGCTGCAGGCCGCCTACGAAGACGGCTTCCACCAGTGTGAC
GCCGGCTGGCTGGCTGACCAGACTGTCAGATACCCCATCCACACTCCCCGGGAAGGCTGC
TATGGAGACAAGGATGAGTTTCCTGGTGTGAGGACGTATGGCATCCGAGACACCAACGAG
ACCTATGATGTGTACTGCTTCGCCGAGGAGATGGAGGGTGAGGTCTTTTATGCAACATCT
CCAGAGAAGTTCACCTTCCAGGAAGCAGCCAATGAGTGCCGGCGGCTGGGTGCCCGGCTG
GCCACCACGGGCCACGTCTACCTGGCCTGGCAGGCTGGCATGGACATGTGCAGCGCCGGC
TGGCTGGCCGACCGCAGCGTGCGCTACCCCATCTCCAAGGCCCGGCCCAACTGCGGTGGC
AACCTCCTGGGCGTGAGGACCGTCTACGTGCATGCCAACCAGACGGGCTACCCCGACCCC
TCATCCCGCTACGACGCCATCTGCTACACAGGTGAAGACTTTGTGGACATCCCAGAAAAC
TTCTTTGGAGTGGGGGGTGAGGAGGACATCACCGTCCAGACAGTGACCTGGCCTGACATG
GAGCTGCCACTGCCTCGAAACATCACTGAGGGTGAAGCCCGAGGCAGCGTGATCCTTACC
GTAAAGCCCATCTTCGAGGTCTCCCCCAGTCCCCTGGAACCCGAGGAGCCCTTCACGTTT
GCCCCTGAAATAGGGGCCACTGCCTTCGCTGAGGTTGAGAATGAGACTGGAGAGGCCACC
AGGCCCTGGGGCTTTCCCACACCTGGCCTGGGCCCTGCCACGGCATTCACCAGTGAGGAC
CTCGTCGTGCAGGTGACCGCTGTCCCTGGGCAGCCGCATTTGCCAGGGGGGGTCGTCTTC
CACTACCGCCCGGGACCCACCCGCTACTCGCTGACCTTTGAGGAGGCACAGCAGGCCTGC
CCTGGCACGGGGGCGGTCATTGCCTCGCCGGAGCAGCTCCAGGCCGCCTACGAAGCAGGC
TATGAGCAGTGTGACGCCGGCTGGCTGCGGGACCAGACCGTCAGATACCCCATTGTGAGC
CCACGGACCCCATGCGTGGGTGACAAGGACAGCAGCCCAGGGGTCAGGACCTATGGCGTG
CGCCCATCAACAGAGACCTACGATGTCTACTGCTTTGTAGACAGACTTGAGGGGGAGGTG
TTCTTCGCCACACGCCTTGAGCAGTTCACCTTCCAGGAAGCACTGGAGTTCTGTGAATCT
CACAATGCCACTGCCACCACGGGCCAGCTCTACGCCGCCTGGAGCCGCGGCCTGGACAAG
TGCTATGCCGGCTGGCTGGCCGACGGCAGCCTCCGCTACCCCATCGTCACCCCAAGGCCT
GCCTGCGGTGGGGACAAGCCAGGCGTGAGAACGGTCTACCTCTACCCTAACCAGACGGGC
CTCCCAGACCCACTGTCCCGGCACCATGCCTTCTGCTTCCGAGGCATTTCAGCGGTTCCT
TCTCCAGGAGAAGAAGAGGGTGGCACACCCACATCACCCTCTGGTGTGGAGGAGTGGATC
GTGACCCAAGTGGTTCCTGGTGTGGCTGCTGTCCCCGTAGAAGAGGAGACAACTGCTGTA
CCCTCAGGGGAGACTACTGCCATCCTAGAGTTCACCACCGAGCCAGAAAACCAGACAGAA
TGGGAACCAGCCTATACCCCAGTGGGCACATCCCCGCTGCCAGGGATCCTTCCTACTTGG
CCTCCTACTGGCGCCGAAACAGAGGAAAGTACAGAAGGCCCTTCTGCAACTGAAGTGCCC
TCTGCCTCAGAGGAACCATCCCCCTCAGAGGTGCCATTCCCCTCAGAGGAGCCATCCCCC
TCAGAGGAACCATTCCCCTCAGTGAGGCCATTCCCCTCAGTGGAGCTGTTCCCCTCAGAG
GAGCCATTCCCCTCCAAGGAGCCATCCCCCTCAGAGGAACCATCAGCCTCAGAAGAGCCG
TATACACCTTCACCCCCCGAGCCCAGCTGGACTGAGCTGCCCAGCTCTGGGGAGGAATCT
GGGGCCCCTGATGTCAGTGGTGACTTCACAGGCAGTGGAGATGTTTCAGGACACCTTGAC
TTCAGTGGGCAGCTGTCAGGGGACAGGGCAAGTGGACTGCCCTCTGGAGACCTGGACTCC
AGTGGTCTTACTTCCACAGTGGGCTCAGGCCTGACTGTGGAAAGTGGACTACCCTCAGGG
GATGAAGAGAGAATTGAGTGGCCCAGCACTCCTACGGTTGGTGAACTGCCCTCTGGAGCT
GAGATCCTAGAGGGCTCTGCCTCTGGAGTTGGGGATCTCAGTGGACTTCCTTCTGGAGAA
GTTCTAGAGACCTCTGCCTCTGGAGTAGGAGACCTCAGTGGGCTTCCTTCTGGAGAAGTT
CTAGAGACCACTGCCCCTGGAGTAGAGGACATCAGCGGGCTTCCTTCTGGAGAAGTTCTA
GAGACCACTGCCCCTGGAGTAGAGGACATCAGCGGGCTTCCTTCTGGAGAAGTTCTAGAG
ACCACTGCCCCTGGAGTAGAGGACATCAGCGGGCTTCCTTCTGGAGAAGTTCTAGAGACC
ACTGCCCCTGGAGTAGAGGACATCAGCGGGCTTCCTTCTGGAGAAGTTCTAGAGACCACT
GCCCCTGGAGTAGAGGACATCAGCGGGCTTCCTTCTGGAGAAGTTCTAGAGACCGCTGCC
CCTGGAGTAGAGGACATCAGCGGGCTTCCTTCTGGAGAAGTTCTAGAGACCGCTGCCCCT
GGAGTAGAGGACATCAGCGGGCTTCCTTCTGGAGAAGTTCTAGAGACCGCTGCCCCTGGA
GTAGAGGACATCAGCGGGCTTCCTTCTGGAGAAGTTCTAGAGACCGCTGCCCCTGGAGTA
GAGGACATCAGCGGGCTTCCTTCTGGAGAAGTTCTAGAGACCGCTGCCCCTGGAGTAGAG
GACATCAGCGGGCTTCCTTCTGGAGAAGTTCTAGAGACCGCTGCCCCTGGAGTAGAGGAC
ATCAGCGGGCTTCCTTCTGGAGAAGTTCTAGAGACCGCTGCCCCTGGAGTAGAGGACATC
AGCGGGCTTCCTTCTGGAGAAGTTCTAGAGACTGCTGCCCCTGGAGTAGAGGACATCAGC
GGGCTTCCTTCTGGAGAAGTTCTAGAGACTGCTGCCCCTGGAGTAGAGGACATCAGCGGG
CTTCCTTCTGGAGAAGTTCTAGAGACTGCTGCCCCTGGAGTAGAGGACATCAGCGGGCTT
CCTTCTGGAGAAGTTCTAGAGACTGCTGCCCCTGGAGTAGAGGACATCAGCGGGCTTCCT
TCTGGAGAAGTTCTAGAGACTACTGCCCCTGGAGTAGAGGAGATCAGCGGGCTTCCTTCT
GGAGAAGTTCTAGAGACTACTGCCCCTGGAGTAGATGAGATCAGTGGGCTTCCTTCTGGA
GAAGTTCTAGAGACTACTGCCCCTGGAGTAGAGGAGATCAGCGGGCTTCCTTCTGGAGAA
GTTCTAGAGACTTCTACCTCTGCGGTAGGGGACCTCAGTGGACTTCCTTCTGGAGGAGAA
GTTCTAGAGATTTCTGTCTCTGGAGTAGAGGACATCAGTGGGCTTCCTTCTGGAGAGGTT
GTAGAGACTTCTGCCTCTGGAATAGAGGATGTCAGTGAACTTCCTTCAGGAGAAGGTCTA
GAGACCTCTGCTTCTGGAGTAGAGGACCTCAGCAGGCTCCCTTCTGGAGAAGAAGTTCTA
GAGATTTCTGCCTCTGGATTTGGGGACCTCAGTGGAGTTCCTTCTGGAGGAGAAGGTCTA
GAGACCTCTGCTTCTGAAGTAGGGACTGACCTCAGTGGGCTTCCTTCTGGAAGGGAGGGT
CTAGAGACTTCAGCTTCTGGAGCTGAGGACCTCAGTGGGTTGCCTTCTGGAAAAGAAGAC
TTGGTGGGGTCAGCTTCTGGAGACTTGGACTTGGGCAAACTGCCTTCTGGAACTCTAGGA
AGTGGGCAAGCTCCAGAAACAAGTGGTCTTCCCTCTGGATTTAGTGGTGAGTATTCTGGG
GTGGACCTTGGAAGTGGCCCACCCTCTGGCCTGCCTGACTTTAGTGGACTTCCATCTGGA
TTCCCAACTGTTTCCCTAGTGGATTCTACATTGGTGGAAGTGGTCACAGCCTCCACTGCA
AGTGAACTGGAAGGGAGGGGAACCATTGGCATCAGTGGTGCAGGAGAAATATCTGGACTG
CCCTCCAGTGAGCTGGACATTAGTGGGAGAGCTAGTGGACTCCCTTCAGGAACTGAACTC
AGTGGCCAAGCATCTGGGTCTCCTGATGTCAGTGGGGAAATACCTGGACTCTTTGGTGTC
AGTGGACAGCCATCAGGGTTTCCTGACACTAGTGGGGAAACATCTGGAGTGACTGAGCTT
AGCGGGCTGTCCTCTGGACAACCAGGTGTTAGTGGAGAAGCATCTGGAGTTCTTTATGGC
ACTAGTCAACCCTTTGGCATAACTGATCTGAGTGGAGAAACATCTGGGGTCCCTGATCTC
AGTGGGCAGCCTTCAGGGTTACCAGGGTTCAGTGGGGCAACATCAGGAGTCCCTGACCTG
GTTTCTGGTACCACGAGTGGCAGCGGTGAATCTTCTGGGATTACATTTGTGGACACCAGT
TTGGTTGAAGTGGCCCCTACTACATTTAAAGAAGAAGAAGGCTTAGGGTCTGTGGAACTC
AGTGGCCTCCCTTCCGGAGAGGCAGATCTGTCAGGCAAATCTGGGATGGTGGATGTCAGT
GGACAGTTTTCTGGAACAGTCGATTCCAGTGGGTTTACATCCCAGACTCCGGAATTCAGT
GGCCTACCAAGTGGCATAGCTGAGGTCAGTGGAGAATCCTCCAGAGCTGAGATTGGGAGC
AGCCTGCCCTCGGGAGCATATTATGGCAGTGGAACTCCATCTAGTTTCCCCACGGTCTCT
CTTGTAGACAGAACTTTGGTGGAATCTGTAACCCAGGCTCCAACAGCCCAAGAGGCAGGA
GAAGGGCCTTCTGGCATTTTAGAACTCAGTGGTGCTCATTCTGGAGCACCAGACATGTCT
GGGGAGCATTCTGGATTTCTGGACCTAAGTGGGCTGCAGTCCGGGCTGATAGAGCCCAGC
GGAGAGCCACCAGGTACTCCATATTTTAGTGGGGATTTTGCCAGCACCACCAATGTAAGT
GGAGAATCCTCTGTAGCCATGGGCACCAGTGGAGAGGCCTCAGGACTTCCAGAAGTTACT
TTAATCACTTCTGAGTTCGTGGAGGGTGTTACTGAACCAACTATTTCTCAGGAACTAGGC
CAAAGGCCCCCTGTGACACACACACCCCAGCTTTTTGAGTCCAGTGGAAAAGTCTCCACA
GCTGGGGACATTAGTGGAGCTACCCCAGTGCTCCCTGGGTCTGGAGTAGAAGTATCATCA
GTCCCAGAATCTAGCAGTGAGACGTCCGCCTATCCTGAAGCTGGGTTCGGGGCATCTGCC
GCCCCTGAGGCCAGCAGAGAAGATTCTGGGTCCCCTGATCTGAGTGAAACCACCTCTGCA
TTCCACGAAGCTAACCTTGAGAGATCCTCTGGCCTAGGAGTGAGCGGCAGCACTTTGACA
TTTCAAGAAGGCGAGGCGTCCGCTGCCCCAGAAGTGAGTGGAGAATCCACCACCACCAGT
GATGTGGGGACAGAGGCACCAGGCTTGCCTTCAGCCACTCCCACGGCTTCTGGAGACAGG
ACTGAAATCAGCGGAGACCTGTCTGGTCACACCTCGCAGCTGGGCGTTGTCATCAGCACC
AGCATCCCAGAGTCTGAGTGGACCCAGCAGACCCAGCGCCCTGCAGAGACGCATCTAGAA
ATTGAGTCCTCAAGCCTCCTGTACTCAGGAGAAGAGACTCACACAGTCGAAACAGCCACC
TCCCCAACAGATGCTTCCATCCCAGCTTCTCCGGAATGGAAACGTGAATCAGAATCAACT
GCTGCAGACCAGGAGGTATGTGAGGAGGGCTGGAACAAGTACCAGGGCCACTGTTACCGC
CACTTCCCGGACCGCGAGACCTGGGTGGATGCTGAGCGCCGGTGTCGGGAGCAGCAGTCA
CACCTGAGCAGCATCGTCACCCCCGAGGAGCAGGAGTTTGTCAACAACAATGCCCAAGAC
TACCAGTGGATCGGCCTGAACGACAGGACCATCGAAGGGGACTTCCGCTGGTCAGATGGA
CACCCCATGCAATTTGAGAACTGGCGCCCCAACCAGCCTGACAACTTTTTTGCCGCTGGA
GAGGACTGTGTGGTGATGATCTGGCACGAGAAGGGCGAGTGGAATGATGTTCCCTGCAAT
TACCACCTCCCCTTCACGTGTAAAAAGGGCACAGCCACCACCTACAAACGCAGACTACAG
AAGCGGAGCTCACGGCACCCTCGGAGGAGCCGCCCCAGCACAGCCCACTGA

# Drug_Target_3_General_Function:
Involved in extracellular matrix structural constituent

# Drug_Target_3_General_References:
1569188	Sandy JD, Flannery CR, Neame PJ, Lohmander LS: The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest. 1992 May;89(5):1512-6.
16080123	Gleghorn L, Ramesar R, Beighton P, Wallis G: A mutation in the variable repeat region of the aggrecan gene (AGC1) causes a form of spondyloepiphyseal dysplasia associated with severe, premature osteoarthritis. Am J Hum Genet. 2005 Sep;77(3):484-90. Epub 2005 Jul 22.
16335952	Liu T, Qian WJ, Gritsenko MA, Camp DG 2nd, Monroe ME, Moore RJ, Smith RD: Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res. 2005 Nov-Dec;4(6):2070-80.
1985970	Doege KJ, Sasaki M, Kimura T, Yamada Y: Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan. Human-specific repeats, and additional alternatively spliced forms. J Biol Chem. 1991 Jan 15;266(2):894-902.
2789216	Baldwin CT, Reginato AM, Prockop DJ: A new epidermal growth factor-like domain in the human core protein for the large cartilage-specific proteoglycan. Evidence for alternative splicing of the domain. J Biol Chem. 1989 Sep 25;264(27):15747-50.
7524681	Glumoff V, Savontaus M, Vehanen J, Vuorio E: Analysis of aggrecan and tenascin gene expression in mouse skeletal tissues by northern and in situ hybridization using species specific cDNA probes. Biochim Biophys Acta. 1994 Nov 22;1219(3):613-22.
7574678	Ilic MZ, Mok MT, Williamson OD, Campbell MA, Hughes CE, Handley CJ: Catabolism of aggrecan by explant cultures of human articular cartilage in the presence of retinoic acid. Arch Biochem Biophys. 1995 Sep 10;322(1):22-30.
7827755	Barry FP, Neame PJ, Sasse J, Pearson D: Length variation in the keratan sulfate domain of mammalian aggrecan. Matrix Biol. 1994 Aug;14(4):323-8.
8216415	Lohmander LS, Neame PJ, Sandy JD: The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum. 1993 Sep;36(9):1214-22.
8611178	Dudhia J, Davidson CM, Wells TM, Vynios DH, Hardingham TE, Bayliss MT: Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage. Biochem J. 1996 Feb 1;313 ( Pt 3):933-40.

# Drug_Target_3_HGNC_ID:
GNC:319

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6607

# Drug_Target_3_Locus:
15q26.1

# Drug_Target_3_Molecular_Weight:
250190.9

# Drug_Target_3_Name:
Aggrecan core protein

# Drug_Target_3_Number_of_Residues:
2415

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00008	EGF
PF00059	Lectin_C
PF00084	Sushi
PF00193	Xlink
PF07686	V-set

# Drug_Target_3_Protein_Sequence:
>Aggrecan core protein
MTTLLWVFVTLRVITAAVTVETSDHDNSLSVSIPQPSPLRVLLGTSLTIPCYFIDPMHPV
TTAPSTAPLAPRIKWSRVSKEKEVVLLVATEGRVRVNSAYQDKVSLPNYPAIPSDATLEV
QSLRSNDSGVYRCEVMHGIEDSEATLEVVVKGIVFHYRAISTRYTLDFDRAQRACLQNSA
IIATPEQLQAAYEDGFHQCDAGWLADQTVRYPIHTPREGCYGDKDEFPGVRTYGIRDTNE
TYDVYCFAEEMEGEVFYATSPEKFTFQEAANECRRLGARLATTGHVYLAWQAGMDMCSAG
WLADRSVRYPISKARPNCGGNLLGVRTVYVHANQTGYPDPSSRYDAICYTGEDFVDIPEN
FFGVGGEEDITVQTVTWPDMELPLPRNITEGEARGSVILTVKPIFEVSPSPLEPEEPFTF
APEIGATAFAEVENETGEATRPWGFPTPGLGPATAFTSEDLVVQVTAVPGQPHLPGGVVF
HYRPGPTRYSLTFEEAQQACPGTGAVIASPEQLQAAYEAGYEQCDAGWLRDQTVRYPIVS
PRTPCVGDKDSSPGVRTYGVRPSTETYDVYCFVDRLEGEVFFATRLEQFTFQEALEFCES
HNATATTGQLYAAWSRGLDKCYAGWLADGSLRYPIVTPRPACGGDKPGVRTVYLYPNQTG
LPDPLSRHHAFCFRGISAVPSPGEEEGGTPTSPSGVEEWIVTQVVPGVAAVPVEEETTAV
PSGETTAILEFTTEPENQTEWEPAYTPVGTSPLPGILPTWPPTGAETEESTEGPSATEVP
SASEEPSPSEVPFPSEEPSPSEEPFPSVRPFPSVELFPSEEPFPSKEPSPSEEPSASEEP
YTPSPPEPSWTELPSSGEESGAPDVSGDFTGSGDVSGHLDFSGQLSGDRASGLPSGDLDS
SGLTSTVGSGLTVESGLPSGDEERIEWPSTPTVGELPSGAEILEGSASGVGDLSGLPSGE
VLETSASGVGDLSGLPSGEVLETTAPGVEDISGLPSGEVLETTAPGVEDISGLPSGEVLE
TTAPGVEDISGLPSGEVLETTAPGVEDISGLPSGEVLETTAPGVEDISGLPSGEVLETAA
PGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGV
EDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDI
SGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGL
PSGEVLETAAPGVEDISGLPSGEVLETTAPGVEEISGLPSGEVLETTAPGVDEISGLPSG
EVLETTAPGVEEISGLPSGEVLETSTSAVGDLSGLPSGGEVLEISVSGVEDISGLPSGEV
VETSASGIEDVSELPSGEGLETSASGVEDLSRLPSGEEVLEISASGFGDLSGVPSGGEGL
ETSASEVGTDLSGLPSGREGLETSASGAEDLSGLPSGKEDLVGSASGDLDLGKLPSGTLG
SGQAPETSGLPSGFSGEYSGVDLGSGPPSGLPDFSGLPSGFPTVSLVDSTLVEVVTASTA
SELEGRGTIGISGAGEISGLPSSELDISGRASGLPSGTELSGQASGSPDVSGEIPGLFGV
SGQPSGFPDTSGETSGVTELSGLSSGQPGVSGEASGVLYGTSQPFGITDLSGETSGVPDL
SGQPSGLPGFSGATSGVPDLVSGTTSGSGESSGITFVDTSLVEVAPTTFKEEEGLGSVEL
SGLPSGEADLSGKSGMVDVSGQFSGTVDSSGFTSQTPEFSGLPSGIAEVSGESSRAEIGS
SLPSGAYYGSGTPSSFPTVSLVDRTLVESVTQAPTAQEAGEGPSGILELSGAHSGAPDMS
GEHSGFLDLSGLQSGLIEPSGEPPGTPYFSGDFASTTNVSGESSVAMGTSGEASGLPEVT
LITSEFVEGVTEPTISQELGQRPPVTHTPQLFESSGKVSTAGDISGATPVLPGSGVEVSS
VPESSSETSAYPEAGFGASAAPEASREDSGSPDLSETTSAFHEANLERSSGLGVSGSTLT
FQEGEASAAPEVSGESTTTSDVGTEAPGLPSATPTASGDRTEISGDLSGHTSQLGVVIST
SIPESEWTQQTQRPAETHLEIESSSLLYSGEETHTVETATSPTDASIPASPEWKRESEST
AAAPARSCAEEPCGAGTCKETEGHVICLCPPGYTGEHCNIDQEVCEEGWNKYQGHCYRHF
PDRETWVDAERRCREQQSHLSSIVTPEEQEFVNNNAQDYQWIGLNDRTIEGDFRWSDGHP
MQFENWRPNQPDNFFAAGEDCVVMIWHEKGEWNDVPCNYHLPFTCKKGTVACGEPPVVEH
ARTFGQKKDRYEINSLVRYQCTEGFVQRHMPTIRCQPSGHWEEPRITCTDATTYKRRLQK
RSSRHPRRSRPSTAH

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-16

# Drug_Target_3_Specific_Function:
This proteoglycan is a major component of extracellular matrix of cartilagenous tissues. A major function of this protein is to resist compression in cartilage. It binds avidly to hyaluronic acid via an N-terminal globular region

# Drug_Target_3_SwissProt_ID:
P16112

# Drug_Target_3_SwissProt_Name:
PGCA_HUMAN

# Drug_Target_3_Synonyms:
Aggrecan core protein 2
CSPCP
Cartilage-specific proteoglycan core protein
Chondroitin sulfate proteoglycan core protein 1

# Drug_Target_3_Theoretical_pI:
3.82

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB02255
